113 results
8-K
EX-10.1
ELDN
Eledon Pharmaceuticals Inc
20 Sep 23
Departure of Directors or Certain Officers
7:09pm
within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days
S-8
ELDN
Eledon Pharmaceuticals Inc
10 Aug 23
Registration of securities for employees
6:28pm
dividends or similar transactions.
(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h
S-8
ELDN
Eledon Pharmaceuticals Inc
10 Aug 23
Registration of securities for employees
6:28pm
on March 24, 2022 (each, Commission File No. 001-36620), as well as any subsequent amendments or reports filed for the purpose of updating
8-K
EX-10.1
uiz7t1nj04p5
21 Jun 23
Departure of Directors or Certain Officers
7:51pm
424B3
0ef5rf82cphbx
8 Jun 23
Prospectus supplement
4:04pm
8-K
EX-10.1
fynb30 kkfcpi6
1 May 23
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
7:27am
8-K
EX-10.2
adrlrb6ao8wmxjyg73
1 May 23
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
7:27am
8-K
EX-4.1
5comsl6u5s
1 May 23
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
7:27am
8-K
EX-4.2
jajgwoi4qrj
1 May 23
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
7:27am